A Randomized Clinical Trial to Evaluate the Effects of Estrogen on Uterine Endometrium in Healthy Postmenopausal Women
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 29
- Primary Endpoint
- Immunohistochemistry (IHC) Proliferative Effects Measurement
Study Overview
Brief Summary
The purpose of this study is to examine the effect of two different dose levels of estrogen or placebo in healthy postmenopausal women by measuring the changes in hormone levels and examining the changes in the uterine lining (endometrium).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Diagnostic
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patient is a healthy postmenopausal woman less than or equal to 65 years of age with onset of menopause less than or equal to 10 years prior to prestudy visit 1
- •Patient has a uterus and no history of uterine bleeding in the past 3 months
- •Patient has not had a previous endometrial biopsy within the last 4 weeks
- •Patient has had a normal mammogram within the last 11 months
- •Patient has had a normal pap-smear within the past 3 years prior to screening
- •Patient has had a normal transvaginal ultrasound of the endometrium
- •Patient is willing to avoid strenuous physical activity such as strenuous or unaccustomed weight lifting, running, bicycling, etc for the duration of the study
- •Patient agrees to not consume grapefruit products beginning approximately 2 weeks prior to the first dose of study drug and throughout the study
- •Patient agrees to limit daily consumption of alcohol. During the study, daily alcohol consumption should not be more than 2 glasses
- •Patient agrees to limit daily consumption of caffeine. During the study, daily caffeine consumption should not exceed 3 cups of coffee
- •Patient is a non-smoker
Exclusion Criteria
- •Patient is mentally or legally incapacitated
- •Patient has a history of any first degree relatives with breast or endometrial cancer
- •Patient has a history of multiple and/or severe allergies to prescription or non-prescription drugs or food
- •Patient has used any type of estrogen or progesterone preparation unless followed by appropriate wash-out periods
- •Patient has had surgery, donated approximately 500 mL of blood or has participated in another investigational study within the last 4 weeks
- •Patient has a history of deep vein thromboses, coronary artery disease, heart attack or stroke
- •Patient is a current user of illegal drugs
- •Patient has a history of hypersensitivity to estrogen products
- •Patient is unable to refrain from using anti-coagulants
Arms & Interventions
17β-estradiol 2.0 milligrams
Estrace 2.0 mg tablet
Intervention: Comparator: Estrace 2 mg (Drug)
17β-estradiol 0.5 milligrams
Estrace 0.5 mg tablet
Intervention: Comparator: Estrace 0.5 mg (Drug)
3
Placebo
Intervention: Comparator: Placebo (Drug)
Outcomes
Primary Outcomes
Immunohistochemistry (IHC) Proliferative Effects Measurement
Time Frame: 4 weeks
Ratio of the total number of positively stained cell nuclei to the total number of cell nuclei. Proliferating endometrial cells express the Ki-67 antigen. The ratio was converted to a percent proliferating cells by taking the number of Ki-67 positive stained nuclei in a given field and dividing by the total number of nuclei in that field and multiplying by 100. At least 5 high power fields were scored in this manner and an aggregate percent Ki-67 positive cells was reported. Square root transformation was taken to make it approximately normally distributed for an ANOVA model to apply.
Secondary Outcomes
- Mean Gene Expression Intensity After 4 Weeks of Either 0.5 or 2 mg Estrace Compared to Placebo.(4 weeks)